APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Radioimmunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Radioimmunotherapy Market Analysis and Forecast 2026-2032

Report ID 173974380229 December 2025208 pages

Choose your research edition.

Industry ResearchCancer Radioimmunotherapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Radioimmunotherapy Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Cancer Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Radioimmunotherapy Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Radioimmunotherapy Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Cancer Radioimmunotherapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cancer Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Radioimmunotherapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cancer Radioimmunotherapy include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cancer Radioimmunotherapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Radioimmunotherapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Cancer Radioimmunotherapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Radioimmunotherapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Radioimmunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cancer Radioimmunotherapy revenue, projected growth trends, production technology, application and end-user industry.

Cancer Radioimmunotherapy Segment by Company

Novartis

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Mundipharma

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Cancer Radioimmunotherapy Segment by Type

Beta-emitting

Targeted Alpha Therapy

Cancer Radioimmunotherapy Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Cancer Radioimmunotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Radioimmunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cancer Radioimmunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cancer Radioimmunotherapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Radioimmunotherapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Radioimmunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Beta-emitting Major Player Table 3. Targeted Alpha Therapy Major Player Table 4. Global Cancer Radioimmunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Solid Tumor Major Player Table 6. Non Hodgkin Lymphoma Major Player Table 7. Cancer Radioimmunotherapy Industry Trends Table 8. Cancer Radioimmunotherapy Industry Drivers Table 9. Cancer Radioimmunotherapy Industry Opportunities and Challenges Table 10. Cancer Radioimmunotherapy Industry Restraints Table 11. Global Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Cancer Radioimmunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Cancer Radioimmunotherapy Market Share by Region (2021-2026) Table 14. Global Cancer Radioimmunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Cancer Radioimmunotherapy Market Share by Region (2027-2032) Table 16. Global Cancer Radioimmunotherapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Cancer Radioimmunotherapy Revenue Market Share by Players (2021-2026) Table 18. Global Cancer Radioimmunotherapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Cancer Radioimmunotherapy Key Players Headquarters & Area Served Table 20. Global Cancer Radioimmunotherapy Players, Product Type & Application Table 21. Global Cancer Radioimmunotherapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Cancer Radioimmunotherapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Cancer Radioimmunotherapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Cancer Radioimmunotherapy Revenue Market Share by Type (2021-2026) Table 28. Global Cancer Radioimmunotherapy Revenue Market Share by Type (2027-2032) Table 29. Global Cancer Radioimmunotherapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Cancer Radioimmunotherapy Revenue Market Share by Application (2021-2026) Table 33. Global Cancer Radioimmunotherapy Revenue Market Share by Application (2027-2032) Table 34. Novartis Company Information Table 35. Novartis Business Overview Table 36. Novartis Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Novartis Cancer Radioimmunotherapy Product Portfolio Table 38. Novartis Recent Development Table 39. Bayer Company Information Table 40. Bayer Business Overview Table 41. Bayer Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Bayer Cancer Radioimmunotherapy Product Portfolio Table 43. Bayer Recent Development Table 44. Y-mAbs Therapeutics Company Information Table 45. Y-mAbs Therapeutics Business Overview Table 46. Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio Table 48. Y-mAbs Therapeutics Recent Development Table 49. Telix Pharmaceuticals Company Information Table 50. Telix Pharmaceuticals Business Overview Table 51. Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 53. Telix Pharmaceuticals Recent Development Table 54. RadioMedix Company Information Table 55. RadioMedix Business Overview Table 56. RadioMedix Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. RadioMedix Cancer Radioimmunotherapy Product Portfolio Table 58. RadioMedix Recent Development Table 59. Philogen Company Information Table 60. Philogen Business Overview Table 61. Philogen Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Philogen Cancer Radioimmunotherapy Product Portfolio Table 63. Philogen Recent Development Table 64. Orano Med Company Information Table 65. Orano Med Business Overview Table 66. Orano Med Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Orano Med Cancer Radioimmunotherapy Product Portfolio Table 68. Orano Med Recent Development Table 69. Nordic Nanovector Company Information Table 70. Nordic Nanovector Business Overview Table 71. Nordic Nanovector Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio Table 73. Nordic Nanovector Recent Development Table 74. Mundipharma Company Information Table 75. Mundipharma Business Overview Table 76. Mundipharma Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Mundipharma Cancer Radioimmunotherapy Product Portfolio Table 78. Mundipharma Recent Development Table 79. Lantheus Company Information Table 80. Lantheus Business Overview Table 81. Lantheus Cancer Radioimmunotherapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Lantheus Cancer Radioimmunotherapy Product Portfolio Table 83. Lantheus Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead Sciences Cancer Radioimmunotherapy Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Fusion Pharmaceuticals Company Information Table 90. Fusion Pharmaceuticals Business Overview Table 91. Fusion Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 93. Fusion Pharmaceuticals Recent Development Table 94. Curium Pharmaceuticals Company Information Table 95. Curium Pharmaceuticals Business Overview Table 96. Curium Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 98. Curium Pharmaceuticals Recent Development Table 99. Curasight Company Information Table 100. Curasight Business Overview Table 101. Curasight Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Curasight Cancer Radioimmunotherapy Product Portfolio Table 103. Curasight Recent Development Table 104. Clarity Pharmaceuticals Company Information Table 105. Clarity Pharmaceuticals Business Overview Table 106. Clarity Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 108. Clarity Pharmaceuticals Recent Development Table 109. China Isotope & Radiation Company Information Table 110. China Isotope & Radiation Business Overview Table 111. China Isotope & Radiation Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio Table 113. China Isotope & Radiation Recent Development Table 114. Aurobindo Pharma Company Information Table 115. Aurobindo Pharma Business Overview Table 116. Aurobindo Pharma Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio Table 118. Aurobindo Pharma Recent Development Table 119. Actinium Pharmaceuticals Company Information Table 120. Actinium Pharmaceuticals Business Overview Table 121. Actinium Pharmaceuticals Cancer Radioimmunotherapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 123. Actinium Pharmaceuticals Recent Development Table 124. North America Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 127. North America Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 128. North America Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Cancer Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 130. North America Cancer Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 131. Europe Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Europe Cancer Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 137. Europe Cancer Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 138. China Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 139. China Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 140. China Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 141. China Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 143. Asia Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 144. Asia Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 145. Asia Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 146. Asia Cancer Radioimmunotherapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Asia Cancer Radioimmunotherapy Revenue by Region (US$ Million) & (2021-2026) Table 148. Asia Cancer Radioimmunotherapy Revenue by Region (US$ Million) & (2027-2032) Table 149. SAMEA Cancer Radioimmunotherapy Revenue by Type (2021-2026) & (US$ Million) Table 150. SAMEA Cancer Radioimmunotherapy Revenue by Type (2027-2032) & (US$ Million) Table 151. SAMEA Cancer Radioimmunotherapy Revenue by Application (2021-2026) & (US$ Million) Table 152. SAMEA Cancer Radioimmunotherapy Revenue by Application (2027-2032) & (US$ Million) Table 153. SAMEA Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. SAMEA Cancer Radioimmunotherapy Revenue by Country (2021-2026) & (US$ Million) Table 155. SAMEA Cancer Radioimmunotherapy Revenue by Country (US$ Million) & (2027-2032) Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Cancer Radioimmunotherapy Image Figure 2. Global Cancer Radioimmunotherapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Radioimmunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Beta-emitting Image Figure 5. Targeted Alpha Therapy Image Figure 6. Global Cancer Radioimmunotherapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Cancer Radioimmunotherapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Solid Tumor Image Figure 9. Non Hodgkin Lymphoma Image Figure 10. Global Cancer Radioimmunotherapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Cancer Radioimmunotherapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Cancer Radioimmunotherapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Cancer Radioimmunotherapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Cancer Radioimmunotherapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cancer Radioimmunotherapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Radioimmunotherapy Revenue Market Share by Type (2021-2032) Figure 18. Global Cancer Radioimmunotherapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Cancer Radioimmunotherapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Cancer Radioimmunotherapy Revenue Market Share by Application (2021-2032) Figure 21. North America Cancer Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Cancer Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 23. North America Cancer Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 24. North America Cancer Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 25. United States Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Cancer Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Cancer Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 30. Europe Cancer Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 31. Europe Cancer Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 32. Germany Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Cancer Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Cancer Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 42. China Cancer Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 43. Asia Cancer Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Cancer Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 45. Asia Cancer Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 46. Asia Cancer Radioimmunotherapy Revenue Share by Region (2021-2032) Figure 47. Japan Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Cancer Radioimmunotherapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Cancer Radioimmunotherapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Cancer Radioimmunotherapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Cancer Radioimmunotherapy Revenue Share by Country (2021-2032) Figure 57. Brazil Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Cancer Radioimmunotherapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Mundipharma
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Radioimmunotherapy Market by Type
  3. 1.2.1 Global Cancer Radioimmunotherapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Beta-emitting
  5. 1.2.3 Targeted Alpha Therapy
  6. 1.3 Cancer Radioimmunotherapy Market by Application
  7. 1.3.1 Global Cancer Radioimmunotherapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Solid Tumor
  9. 1.3.3 Non Hodgkin Lymphoma
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Cancer Radioimmunotherapy Market Dynamics
  1. 2.1 Cancer Radioimmunotherapy Industry Trends
  2. 2.2 Cancer Radioimmunotherapy Industry Drivers
  3. 2.3 Cancer Radioimmunotherapy Industry Opportunities and Challenges
  4. 2.4 Cancer Radioimmunotherapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cancer Radioimmunotherapy Market Perspective (2021-2032)
  2. 3.2 Global Cancer Radioimmunotherapy Growth Trends by Region
  3. 3.2.1 Global Cancer Radioimmunotherapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Radioimmunotherapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Cancer Radioimmunotherapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cancer Radioimmunotherapy Revenue by Players
  2. 4.1.1 Global Cancer Radioimmunotherapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Cancer Radioimmunotherapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cancer Radioimmunotherapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Radioimmunotherapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cancer Radioimmunotherapy Key Players Headquarters & Area Served
  7. 4.4 Global Cancer Radioimmunotherapy Players, Product Type & Application
  8. 4.5 Global Cancer Radioimmunotherapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cancer Radioimmunotherapy Market CR5 and HHI
  11. 4.6.3 2025 Cancer Radioimmunotherapy Tier 1, Tier 2, and Tier 3
5 Cancer Radioimmunotherapy Market Size by Type
  1. 5.1 Global Cancer Radioimmunotherapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 5.3 Global Cancer Radioimmunotherapy Revenue Market Share by Type (2021-2032)
6 Cancer Radioimmunotherapy Market Size by Application
  1. 6.1 Global Cancer Radioimmunotherapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  3. 6.3 Global Cancer Radioimmunotherapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Cancer Radioimmunotherapy Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Cancer Radioimmunotherapy Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Y-mAbs Therapeutics
  14. 7.3.1 Y-mAbs Therapeutics Company Information
  15. 7.3.2 Y-mAbs Therapeutics Business Overview
  16. 7.3.3 Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio
  18. 7.3.5 Y-mAbs Therapeutics Recent Developments
  19. 7.4 Telix Pharmaceuticals
  20. 7.4.1 Telix Pharmaceuticals Company Information
  21. 7.4.2 Telix Pharmaceuticals Business Overview
  22. 7.4.3 Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  24. 7.4.5 Telix Pharmaceuticals Recent Developments
  25. 7.5 RadioMedix
  26. 7.5.1 RadioMedix Company Information
  27. 7.5.2 RadioMedix Business Overview
  28. 7.5.3 RadioMedix Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 RadioMedix Cancer Radioimmunotherapy Product Portfolio
  30. 7.5.5 RadioMedix Recent Developments
  31. 7.6 Philogen
  32. 7.6.1 Philogen Company Information
  33. 7.6.2 Philogen Business Overview
  34. 7.6.3 Philogen Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Philogen Cancer Radioimmunotherapy Product Portfolio
  36. 7.6.5 Philogen Recent Developments
  37. 7.7 Orano Med
  38. 7.7.1 Orano Med Company Information
  39. 7.7.2 Orano Med Business Overview
  40. 7.7.3 Orano Med Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Orano Med Cancer Radioimmunotherapy Product Portfolio
  42. 7.7.5 Orano Med Recent Developments
  43. 7.8 Nordic Nanovector
  44. 7.8.1 Nordic Nanovector Company Information
  45. 7.8.2 Nordic Nanovector Business Overview
  46. 7.8.3 Nordic Nanovector Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio
  48. 7.8.5 Nordic Nanovector Recent Developments
  49. 7.9 Mundipharma
  50. 7.9.1 Mundipharma Company Information
  51. 7.9.2 Mundipharma Business Overview
  52. 7.9.3 Mundipharma Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mundipharma Cancer Radioimmunotherapy Product Portfolio
  54. 7.9.5 Mundipharma Recent Developments
  55. 7.10 Lantheus
  56. 7.10.1 Lantheus Company Information
  57. 7.10.2 Lantheus Business Overview
  58. 7.10.3 Lantheus Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lantheus Cancer Radioimmunotherapy Product Portfolio
  60. 7.10.5 Lantheus Recent Developments
  61. 7.11 Gilead Sciences
  62. 7.11.1 Gilead Sciences Company Information
  63. 7.11.2 Gilead Sciences Business Overview
  64. 7.11.3 Gilead Sciences Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Gilead Sciences Cancer Radioimmunotherapy Product Portfolio
  66. 7.11.5 Gilead Sciences Recent Developments
  67. 7.12 Fusion Pharmaceuticals
  68. 7.12.1 Fusion Pharmaceuticals Company Information
  69. 7.12.2 Fusion Pharmaceuticals Business Overview
  70. 7.12.3 Fusion Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  72. 7.12.5 Fusion Pharmaceuticals Recent Developments
  73. 7.13 Curium Pharmaceuticals
  74. 7.13.1 Curium Pharmaceuticals Company Information
  75. 7.13.2 Curium Pharmaceuticals Business Overview
  76. 7.13.3 Curium Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  78. 7.13.5 Curium Pharmaceuticals Recent Developments
  79. 7.14 Curasight
  80. 7.14.1 Curasight Company Information
  81. 7.14.2 Curasight Business Overview
  82. 7.14.3 Curasight Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Curasight Cancer Radioimmunotherapy Product Portfolio
  84. 7.14.5 Curasight Recent Developments
  85. 7.15 Clarity Pharmaceuticals
  86. 7.15.1 Clarity Pharmaceuticals Company Information
  87. 7.15.2 Clarity Pharmaceuticals Business Overview
  88. 7.15.3 Clarity Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  90. 7.15.5 Clarity Pharmaceuticals Recent Developments
  91. 7.16 China Isotope & Radiation
  92. 7.16.1 China Isotope & Radiation Company Information
  93. 7.16.2 China Isotope & Radiation Business Overview
  94. 7.16.3 China Isotope & Radiation Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  95. 7.16.4 China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio
  96. 7.16.5 China Isotope & Radiation Recent Developments
  97. 7.17 Aurobindo Pharma
  98. 7.17.1 Aurobindo Pharma Company Information
  99. 7.17.2 Aurobindo Pharma Business Overview
  100. 7.17.3 Aurobindo Pharma Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio
  102. 7.17.5 Aurobindo Pharma Recent Developments
  103. 7.18 Actinium Pharmaceuticals
  104. 7.18.1 Actinium Pharmaceuticals Company Information
  105. 7.18.2 Actinium Pharmaceuticals Business Overview
  106. 7.18.3 Actinium Pharmaceuticals Cancer Radioimmunotherapy Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  108. 7.18.5 Actinium Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Cancer Radioimmunotherapy Revenue (2021-2032)
  2. 8.2 North America Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Cancer Radioimmunotherapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Cancer Radioimmunotherapy Revenue by Type (2027-2032)
  5. 8.3 North America Cancer Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Cancer Radioimmunotherapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Cancer Radioimmunotherapy Revenue by Application (2027-2032)
  9. 8.5 North America Cancer Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Cancer Radioimmunotherapy Revenue by Country
  11. 8.6.1 North America Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cancer Radioimmunotherapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Cancer Radioimmunotherapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Radioimmunotherapy Revenue (2021-2032)
  2. 9.2 Europe Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cancer Radioimmunotherapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cancer Radioimmunotherapy Revenue by Type (2027-2032)
  5. 9.3 Europe Cancer Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cancer Radioimmunotherapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cancer Radioimmunotherapy Revenue by Application (2027-2032)
  9. 9.5 Europe Cancer Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cancer Radioimmunotherapy Revenue by Country
  11. 9.6.1 Europe Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cancer Radioimmunotherapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cancer Radioimmunotherapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cancer Radioimmunotherapy Revenue (2021-2032)
  2. 10.2 China Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 10.2.1 China Cancer Radioimmunotherapy Revenue by Type (2021-2026)
  4. 10.2.2 China Cancer Radioimmunotherapy Revenue by Type (2027-2032)
  5. 10.3 China Cancer Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 10.4 China Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  7. 10.4.1 China Cancer Radioimmunotherapy Revenue by Application (2021-2026)
  8. 10.4.2 China Cancer Radioimmunotherapy Revenue by Application (2027-2032)
  9. 10.5 China Cancer Radioimmunotherapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Radioimmunotherapy Revenue (2021-2032)
  2. 11.2 Asia Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cancer Radioimmunotherapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cancer Radioimmunotherapy Revenue by Type (2027-2032)
  5. 11.3 Asia Cancer Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cancer Radioimmunotherapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cancer Radioimmunotherapy Revenue by Application (2027-2032)
  9. 11.5 Asia Cancer Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cancer Radioimmunotherapy Revenue by Country
  11. 11.6.1 Asia Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cancer Radioimmunotherapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cancer Radioimmunotherapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Radioimmunotherapy Revenue (2021-2032)
  2. 12.2 SAMEA Cancer Radioimmunotherapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cancer Radioimmunotherapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cancer Radioimmunotherapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cancer Radioimmunotherapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cancer Radioimmunotherapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cancer Radioimmunotherapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cancer Radioimmunotherapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cancer Radioimmunotherapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cancer Radioimmunotherapy Revenue by Country
  11. 12.6.1 SAMEA Cancer Radioimmunotherapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cancer Radioimmunotherapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cancer Radioimmunotherapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst